Ten-Year Longitudinal Study of Thyroid Function in Children with Down’s Syndrome

Lorenzo Iughetti a, Barbara Predieri a, Patrizia Bruzzi a, Flavia Predieri a, Giulia Vellani a, Simona Filomena Madeo a, Livia Garavelli b, Ornella Biagioni c, Giorgio Bedogni d, Mauro Bozzola e

a Department of Medical and Surgical Sciences of the Mother, Children and Adults, University of Modena and Reggio Emilia, Modena, b Clinical Genetics Unit, Obstetric and Pediatric Department, Istituto di Ricovero e Cura a Carattere Scientifico, Arcispedale Santa Maria Nuova, Reggio Emilia, c Department of Mental Health, AUSL, Modena, d Liver Research Center, Basovizza, Trieste, and International Center for the Assessment of Nutritional Status (ICANS), University of Milan, Milan, and e Internal Medicine and Therapeutics Department, University of Pavia, Pavia, Italy

6.1). Diffuse hypoechogenicity on thyroid ultrasound was found in 34 out of 145 children. Conclusion: The probability of thyroid dysfunction increasing during development is higher than previously reported. Such children should be carefully monitored annually to early identify thyroid dysfunction. © 2014 S. Karger AG, Basel

Introduction

Down’s syndrome (DS), the most common chromosomal disorder, is associated with several concomitant diseases, including thyroid dysfunction [1–3]. Thyroid disorders are more common in patients with DS than in the general population and they have been estimated to range between 4 and 19.5% [4–8] with an increase in frequency, up to 54%, as the children age [5, 9, 10]. These abnormalities include congenital hypothyroidism (1–3.6%) [7, 11–14], primary hypothyroidism (0.3–3.2%) [7, 14, 15], autoimmune thyroiditis (0.3–1.4%) [16], and subclinical hypothyroidism (12.5–32.9%) [7, 10, 14, 15, 17]. In addition, hyperthyroidism (0–2%) occurs in children with DS as well [7, 10, 18].
Pathogenesis, natural course, prognostic factors, and therapy of thyroid dysfunction in children with DS remain the objects of debate in the literature because epidemiological and long-term cohort studies are scarce. Pediatric endocrinologists frequently face the decision of what to do regarding these subjects.

In the general population the natural history of Hashimoto’s thyroiditis in children and adolescents is not yet fully known. TSH concentrations showed large fluctuations over time, and a trend toward progressively deteriorating thyroid function was demonstrated [19, 20]. A recent review on subclinical hypothyroidism in children showed that it is a remitting process with a rate of evolution toward overt hypothyroidism ranging between 0 and 28.8% [21].

We hypothesized that the occurrence of thyroid diseases in children with DS rises in the course of development. Therefore, we investigated the probability of each thyroid disease in a cohort of 145 children with DS from birth to 10 years of age.

**Subjects and Methods**

**Clinical and Biochemical Assessment**

We conducted a cohort study from 1995 to 2010 including 205 Caucasian neonates with DS (95.6% with primary trisomy 21, 3.4% with translocation, and 1% with mosaicism) assessed at the Department of Pediatrics of the University of Modena and Reggio Emilia, Italy. 20 neonates were not recruited because the parents refused the study, while during the follow-up children were excluded because of the development of severe heart disease in 18 cases, leukemia in 4, seizure in 3, and celiac disease in 10. We include this description of these subjects to avoid the lost to follow-up because of sudden death [22] and the diagnostic bias due to other exposure status. Specifically, patients with known autoimmune diseases [23] or using drugs that may interfere with thyroid function [24, 25] are prone to develop autoimmune thyroiditis or subclinical hypothyroidism. Furthermore, 2 subjects refused to continue the study and 3 were lost to follow-up. Written informed consent was obtained from all parents at the moment of recruitment in the study and before the first data collection. The study was approved by the Ethics Committee of the University of Modena and Reggio Emilia.

Thyroid function status was tested annually from birth over a 10-year period. Blood samples were analyzed for thyroid-stimulating hormone (TSH), free thyroxine (fT4), thyroglobulin antibody (TGab), and thyroid peroxidase antibody (TPOab) within the same laboratory. Plasma TSH and fT4 were measured by fluorometric assay (AutoDELFIa automatic immunoassay system). TGab and TPOab were quantified by an immunometric assay (IMMULITE 2000): values >40 and >35 IU/ml were defined as positive, respectively. Ultrasonography of thyroid gland was performed by an experienced pediatric radiologist who was blinded to the thyroid status of the subjects. In subjects with congenital hypothyroidism (C-HT) it was immediately performed while in the others it was first done at 2 years of age and repeated at time of thyroid dysfunction and/or thyroid autoantibodies development. In these cases a 2-year thyroid ultrasound follow-up was performed.

After exclusion of children with confirmed C-HT (newborn screening based on the measurement of TSH ≥20 μIU/ml on eluates of dry blood collected on filter paper after 24 h of life as the primary screening test and confirmed by plasma thyroid function test performed after 8 days of life), all DS children were annually grouped according to both fT4 and TSH levels as: (a) euthyroidism (EuT): normal fT4 and TSH ≤5 μIU/ml; (b) hypothyroidism (HT): low fT4 and TSH ≥10 μIU/ml; (c) subclinical HT (S-HT): normal fT4 and TSH >5 μIU/ml; and (d) hyperthyroidism (HyperT): high fT4 and low TSH.

Children with C-HT were excluded from the present prospective analysis, but not at first year evaluation of thyroid dysfunction probability. Subjects with HT were treated with l-thyroxine and were considered in HT group during the whole follow-up period. Replacement therapy was also started in children with S-HT but only if TSH levels were persistently ≥10 μIU/ml [21] and these patients have always been included in the S-HT group.

**Statistical Analysis**

Heteroskedastic binary and ordinal logistic regression for repeated measures was used to evaluate the changes of the binary and ordinal outcomes of interest with time [26, 27]. These analyses were implemented using a heteroskedastic ordinal generalized linear model (OGLM) with cluster confidence intervals to take into account repeated measures. The OGLM reduces to a logistic regression model when the outcome is binary and estimates the odds of more severe versus less severe disease when the outcome is ordinal. The binary outcomes of interest were: (1) thyroid dysfunction (0 = no; 1 = yes), (2) TGab positivity (0 = no; 1 = yes), and TPOab positivity (0 = no; 1 = yes). The ordinal outcome of interest was HT (0 = EuT, 1 = S-HT, and 2 = overt HT). Time was modeled as continuous (years 1–10 by steps of 1) and the possibility to control for heteroskedasticity was used to model non-linear time-outcome relationships. To test whether TGab and TPOab are associated with HT, we added them, first separately and then together, with time as predictors of the logistic ordinal model (multivariable analysis). The odds ratio (OR) associated with TGab and TPOab is a time-averaged measure of their association with HT. Statistical significance was set to a value of p < 0.05. Statistical analysis was performed using STATA MP Version 13.0.

**Results**

From 1995 to 2010, 145 of 205 patients with DS were longitudinally evaluated for the purpose of the study. Overall, 59% of the subjects were boys. During the first year of evaluation, C-HT was confirmed in 10 of 145 cases (6.9%; 6 out 10 had thyroid agenesis, 2 had thyroid ectopia, and 2 had thyroid hypoplasia), 4 children had HT (2.7%; with normal thyroid ultrasound characteristics), 27 had S-HT (18.6%; 2 out of 27 had thyroid hypoplasia...
and 1 year after developed thyroid autoantibodies), while the other 104 had normal thyroid function.

Figure 1 depicts the probability of any thyroid dysfunction during the study. Such probability increased from 30% (95% CI 24–37) at the 1st year to 49% (95% CI 41–58) at the 10th year (p < 0.001, heteroskedastic binary logistic regression with cluster confidence intervals). Thyroid dysfunction was classified as HyperT in 1 case and as S-HT or overt HT in the remaining cases. Further analyses were performed on the subjects who did not develop HyperT.

Figure 2 depicts the probability of EuT, S-HT and overt HT during the follow-up. The probability of EuT decreased from 71% (65–78%) at the 1st year to 52% (44–60%) at the 10th year. S-HT had a fluctuating course between normal, compensated and overt HT, so its probability was nearly stable, being 22% (17–28%) at the 1st year and 24% (17–31%) at the 10th year. Lastly, the probability of overt HT increased from 7% (3–10%) at the 1st year to 24% (17–32%) at the 10th year (p < 0.001, heteroskedastic ordinal logistic regression with cluster confidence intervals).

Considering the EuT group, we found that after 10 years, 64 patients still had normal function, 17 developed HT, and 22 developed S-HT. In the S-HT group, one third developed EuT at the end of the study without replacement therapy, while one third developed HT. The thyroid dysfunctions were almost equally distributed between the genders (data not show).

Figures 3 and 4 depict the probability of positive thyroid autoantibodies (ATA) during the study. The probability of positive TGab increased from 3% (5% to 5%) at the 1st year to 25% (17–33%) at the 10th year with corresponding figures of 5% (2–7%) and 37% (30–45%) for TPOab (p < 0.001, heteroskedastic binary logistic regression with cluster confidence intervals) (fig. 3). The sig-
A significant increase in the probability of ATA was mainly found in subjects with EuT (32 out of 99 initially negative, 32.3%) and S-HT (14 out of 27 initially negative, 51.8%) (fig. 4).

Combining the data according to thyroid function and the development of ATA over a 10-year period, we found two different natural course patterns for both EuT and S-HT, mainly depending on the presence or absence of ATA. In particular, 60% of ATA-positive EuT subjects developed a thyroid dysfunction, whereas 73% of ATA-negative EuT cases remained in EuT group (p = 0.002). Among children with S-HT at first visit, 50% of ATA-positive cases had not changed at the last visit, whereas 28.6% developed HT. This prevalence was lower than in ATA-negative cases (38.5%); only 21.4% of ATA-positive subjects developed EuT, in contrast to the 46.1% we found among the ATA-negative cases (fig. 5).

At multivariable ordinal logistic regression, TGab positivity was associated with higher odds of more severe versus less severe HT but the estimate was imprecise (OR 3.6, 95% CI 1.2–11.0, p = 0.02). On the contrary, TPOab positivity was strongly associated with more severe versus less severe HT (OR 6.1, 95% CI 2.3–16.1, p < 0.001). Adding TGab to TPOab was associated with no improvement in the prediction of the severity of HT as compared to TPOab alone (OGLM not shown).

The characteristics of thyroid ultrasounds at the 10-year follow-up are reported in table 1. Overall, 62% of subjects had normal echogenicity on ultrasound and 23.5% had diffuse hypoechochogenicity (p < 0.001). The prevalence of thyroid dysfunctions in children with hypoechochogenicity was significantly higher than in individuals with normal thyroid echogenicity (61.8 vs. 37.8%, p = 0.028). Considering ATA status, we found that subjects with hypoechochogenicity had a significantly higher percentage of ATA positivity than those with normal echogenicity (70.6 vs. 31.0%, p < 0.001). Interestingly, all subjects with diffuse hypoechochogenicity on thyroid ultrasound but no circulating ATA (29.4%) had thyroid dysfunctions (6 S-HT and 4 HT) (table 2).

After exclusion of patients with C-HT, at the end of the follow-up, 55 (41%) of our children were treated for thyroid disorders. Specifically, L-thyroxine replacement therapy was started in all children who developed HT and in 24 out of 31 (77.5%) patients with S-HT. Almost all patients with ATA-positive S-HT (88%) required treat...
Thyroid Dysfunction in Down’s Syndrome Children

To assess the possibility that the level of initial TSH was predictive of a future thyroid dysfunction requiring L-thyroxine replacement therapy, we correlated the 1st year TSH values with the ones just before therapy. Excluding data from the C-HT patients and the 4 subjects already having HT at 1 year of life, the TSH levels at the 1st year (4.92 ± 1.83 μIU/ml) and the ones just before therapy (12.3 ± 13.5 μIU/ml) were not significantly correlated (Spearman R = 0.234, p = 0.098). The same results were observed analyzing data according to 1st year.

Fig. 4. Anti-thyroid antibodies: changes of TGab and TPOab according to thyroid status.
thyroid function: EuT (Spearman R = 0.060, p = 0.7322) and S-HT (Spearman R = 0.317, p = 0.230). Moreover, considering data from DS patients with S-HT at the end of the study, we found that both TSH (Spearman R = -0.063, p = 0.737) and fT₄ (Spearman R = 0.069, p = 0.710) levels were not significantly correlated with BMI z-score.

### Discussion

Several studies have investigated the prevalence of thyroid dysfunction in children and adults with DS [4, 10–12, 14, 15, 28, 29] but, to our best knowledge, this is the first prospective study to examine annually, over a 10-year period, the natural history of thyroid disorders in very young children with DS. Our data confirm the high probability of thyroid dysfunctions in children with DS, increasing year by year, when compared to reference ranges for the general population.

In our cohort, C-HT probability was higher than reported in the literature, ranging from 1 to 2.7% [11–13]. Early thyroid screening increases the prevalence of newborns demonstrating a modest elevation of blood spot TSH concentrations due to the physiological neonatal surge, increasing the number of false-positive results. Newborns with DS generally have a mild hypothyroid state because of decreased thyroxine concentration that left-shifted normal distribution and mildly elevated TSH levels [30]. To avoid false-positive C-HT due to early measurement, we used a TSH screening cut-off of ≥20 μIU/ml and this allowed us to exclude additional cases of C-HT that were mainly due to functional disorders [31]. Moreover, to confirm the positive screening C-HT cases, we adopted a diagnostic algorithm that included the sub-

### Table 1. Thyroid ultrasound characteristics according to thyroid status at the 10th year

| Thyroid ultrasound characteristics at the 10th year (ATA status at the 10th year) | Thyroid status at the 10th year (ATA status at the 10th year) |
|---|---|---|---|---|---|
| Normal (90) | EuT (73) | C-HT (10) | HT (30) | S-HT (31) | HyperT (1) |
| ATA-positive (28/90) | 56 (76.7%) | – | 17 (56.7%) | 17 (54.8%) | – |
| | 10 (13.7%) | – | 8 (26.7%) | 10 (32.3%) | – |
| Hypoplasia (12) | 4 (5.5%) | 2 (20%) | 2 (6.6%) | 4 (13.0%) | – |
| ATA-positive (1/12) | – | – | – | 1 (3.2%) | – |
| Agenesis (6) | – | 6 (60%) | – | – | – |
| Ectopia (2) | – | 2 (20%) | – | – | – |
| Nodule (1) | – | – | – | 1 (3.2%) | – |
| ATA-positive (1/1) | – | – | – | 1 (3.2%) | – |
| Diffuse hypoecogenicity (34) | 13 (17.8%) | – | 11 (36.7%) | 9 (29.0%) | 1 (100%) |
| ATA-positive (24/34) | 13 (17.8%) | – | 7 (23.3%) | 3 (9.7%) | 1 (100%) |

Data are reported as number of subjects and % according to thyroid status.
sequent confirmation by low plasma fT4, high TSH levels and thyroid ultrasound characteristics (6 agenesis, 2 ec-
topia, and 2 hypoplasia).

Our children with DS suffered from two other differ-
ent thyroid diseases such as S-HT mainly developed dur-
ning the first 3 years of life and HT with a later onset; how-
ever, these thyroid dysfunctions were both present as ear-
ly as the 1st year of life. These cases of S-HT and HT,
considering the thyroid ultrasound characteristics and
the development of ATA, cannot be misdiagnosed with
C-HT. Beyond the neonatal period, the incidence of ele-
vated TSH values in DS increases, being reported as high
as 85% of infants under the age of 12 months [32].

Despite the limitation of the low number and the high
heterogeneity of patients included in the published studies,
in the general population S-HT is a benign and remit-
ting process with a risk of progression to overt HT of ap-
proximately 0–12.5% [19, 21, 33–35]. In a retrospective
multicenter study [34], including a large pediatric cohort,
it was demonstrated that TSH values tended to normalize
proportionally to the degree of the TSH elevation at the
initiation of the study. In subjects with TSH between 5.5
and 10 μIU/ml, 73.6% normalized their TSH, about 25%
maintained that range, and about 2% had their TSH in-
creased over 10 μIU/ml but with normal fT4. In subjects
with initially highly elevated TSH, 40% normalized their
TSH, 33.1% reduced their TSH to a value between 5.5 and
10 μIU/ml, 24.9% maintained their TSH higher than 10
μIU/ml. Overall, 70.1% of initially abnormal TSH levels
normalize in the second evaluation while HT requiring
replacement therapy was found in 0.4% of the cohort.

In our cohort we found that an increase in TSH levels
such to support the definition of S-HT is not correlated
with BMI z-score and may be considered a common tran-
sient condition in DS and not necessarily imply the oc-
currence of HT. Considering our data, we recommend a
careful approach and follow-up for children with DS, thy-
roid hypoplasia and S-HT, irrespective of the presence or
absence of ATA. A recent study demonstrated that the
distribution plot for TSH had a significant shift of the
curve to higher values in subjects with DS respect to
healthy controls, suggesting that hyperthyrotropinemia is
an innate attribute of chromosome 21 trisomy [36].
Moreover, some authors [5, 37, 38] have proposed that
S-HT is probably related to inappropriate secretion of
TSH or thyroid insensitivity to TSH, rather than to auto-
immune thyroiditis.

As well as an increase in the probability of thyroid dys-
function, we also found an increased probability of ATA
during the 10-year period. It is important to note that in
our EuT children, the presence of ATA, mainly TPOab,
significantly raised the risk of developing thyroid dys-

<table>
<thead>
<tr>
<th>Thyroid ultrasound characteristics at the 10th year</th>
<th>Thyroid status at the 10th year</th>
<th>ATA status at the 10th year</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EuT</td>
<td>TPOab+ (24)</td>
</tr>
<tr>
<td>Normal (90)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EuT</td>
<td>4 (4.4%)</td>
<td>20 (22.2%)</td>
</tr>
<tr>
<td>HT</td>
<td>2 (2.2%)</td>
<td>8 (8.9%)</td>
</tr>
<tr>
<td>S-HT</td>
<td>1 (1.1%)</td>
<td>7 (7.8%)</td>
</tr>
<tr>
<td></td>
<td>1 (1.1%)</td>
<td>5 (5.5%)</td>
</tr>
<tr>
<td>Hypoplasia (10)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EuT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HT</td>
<td>1 (10%)</td>
<td></td>
</tr>
<tr>
<td>S-HT</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 (10%)</td>
<td></td>
</tr>
<tr>
<td>Nodule (1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EuT</td>
<td>1 (100%)</td>
<td></td>
</tr>
<tr>
<td>HT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S-HT</td>
<td>1 (100%)</td>
<td></td>
</tr>
<tr>
<td>Diffuse hypoechochogenicity (34)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EuT</td>
<td>19 (55.9%)</td>
<td>3 (8.8%)</td>
</tr>
<tr>
<td>HT</td>
<td>8 (23.6%)</td>
<td>3 (8.8%)</td>
</tr>
<tr>
<td>S-HT</td>
<td>7 (20.6%)</td>
<td></td>
</tr>
<tr>
<td>HyperT</td>
<td>3 (8.8%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 (2.9%)</td>
<td></td>
</tr>
</tbody>
</table>

Data are reported as number of subjects and % according to thyroid ultrasound characteristics (patients with C-HT were all negative for ATA so their data were excluded from the table).
functions during the long-term follow-up. These data suggest that ATA might represent a marker of deteriorating thyroid function unlike 1st year TSH levels that do not predict future thyroid dysfunction requiring therapy, both in initially EuT and S-HT subjects with DS.

The prevalence of ATA in DS children was reported to range from 16% [38] to 39% [39]. Moreover, the increased TSH levels were demonstrated to be positively correlated with TPOab which were already indicated as a key factor in the follow-up of DS subjects [40]. So, our results have confirmed the previously reported findings on the important role of both elevated TSH and ATA in the development of HT [10, 14, 16, 17, 39, 41], suggesting that children with DS should be tested more frequently than others.

In the general population it was demonstrated that in children and adolescents with both S-HT and autoimmune thyroiditis ATA increased over time [19, 35]. However, the progressive increase in TPOab raised the risk of developing HT by 3.5-fold [20], lower than data we found in our DS population.

Up to 10% of patients with autoimmune thyroiditis are ATA-negative [42], so thyroid ultrasound findings may be important in order to differentiate children with a mild S-HT and autoimmune thyroiditis from those with other causes of thyroid dysfunction. Our data support the hypothesis that some children with DS may have a persistent mild HT presumably of thyroidal origin related to the trisomic state of chromosome 21 [43].

Thyroid hormones influence almost all aspects of normal development during childhood. They play a crucial role as regulators of neurodevelopment, growth and skeletal development, and metabolism [44]. The early diagnosis of thyroid dysfunctions is important and pediatricians can often recognize them in their early stages, by maintaining an appropriate index of suspicion. Recognition of HT can be very difficult because it has a subtle presentation and symptoms overlap with features of DS, including impaired intellectual development in young children, decreased linear growth, dry skin and fine hair, excess weight, dentition abnormalities, and decreased physical activity [2]. In our DS children with thyroid dysfunctions the incidence of replacement therapy was 41% over the 10-year period. The medical treatment of S-HT is a topic of debate [5, 11, 14], however almost all patients with ATA required treatment [45]. Currently we do not know at which TSH level clinical signs and potential adverse effects on lipid profile, cardiac function, and neuropsychiatric performance will appear, or whether treatment can prevent them. However, it was demonstrated that S-HT, even of many years’ duration, and HT, if appropriately treated within a few months, do not impair growth [19]. In the general pediatric population, there is no clear evidence of the beneficial effects of L-thyroxine on growth and thyroid volume [21], but van Trotsenburg et al. [46] have reported that in children with DS replacement therapy for the first 24 months of life probably results in improvements of psychomotor development and growth. However, this study was designed to determine the rate of annual thyroid dysfunctions in this population, not the appropriateness of treatment.

In summary, in our study, thyroid dysfunctions were relatively common in children with DS and because symptoms might be mistaken for symptoms related to the natural course of DS they may represent a significant health risk if not identified. We suggest that DS patients, especially those with EuT or S-TH associated with positive ATA, should be annually monitored to precociously identify thyroid diseases and to begin an adequate replacement therapy when proper.

Disclosure Statement

The authors have no conflicts of interest to disclose.

References


8 Horm Res Paediatr
DOI: 10.1159/000362450

Iughetti et al.
Thyroid Dysfunction in Down’s Syndrome Children

Horn Res Paediart
DOI: 10.1159/000362450


